ArticleFrontiers in neuroscience2026
Effects of individualized phase-amplitude-coupled transcranial alternating current stimulation on tinnitus and cognition.
Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic tinnitus is a prevalent and disabling condition that is frequently accompanied by domain-specific cognitive difficulties. Abnormal neural oscillations and disrupted cross-frequency coupling (CFC) have been implicated in its pathophysiology. This study investigated whether individualized phase-amplitude-coupled transcranial alternating current stimulation (tACS), tailored to each participant's individual alpha frequency (IAF), was associated with changes in tinnitus symptoms, cognition, and neurophysiological measures. Methods: In this prospective single-arm interventional study, 25 adults with chronic tinnitus (>6 months) were enrolled, and 21 completed the protocol. Participants received five sessions of individualized IAF-based phase-amplitude-coupled tACS at 2 mA for 20 min per session. Tinnitus outcomes included the Tinnitus Handicap Inventory (THI) and visual analog scale ratings of loudness (VAS-L) and annoyance (VAS-A). Cognitive performance was assessed using the Montreal Cognitive Assessment, Trail Making Tests A and B, Digit Span Tests forward and backward (DST-F/B), and Symbol Digit Modalities Test (SDMT). Electroencephalography-based spectral and CFC analyses were conducted in an artifact-free subgroup of 10 participants. Results: THI scores decreased significantly over the course of the intervention, whereas VAS-L and VAS-A showed no significant group-level changes. Cognitive performance improved across global cognition, processing speed, executive function, and working memory. Repeated-measures analyses demonstrated significant session effects for DST-F, DST-B, and SDMT. DST-B also showed a significant overall pre- to post-stimulation effect, whereas this effect was marginal for DST-F and absent for SDMT; no significant tACS × session interactions were observed. CFC analyses showed no significant pre- to post-stimulation changes after correction for multiple comparisons. Conclusion: Repeated individualized IAF-based phase-amplitude-coupled tACS was associated with reduced tinnitus-related functional impact and improvements in several cognitive measures, whereas subjective loudness and annoyance did not change significantly at the group level. No robust group-level CFC changes were detected. Given the single-arm design and absence of sham control, these findings are preliminary and do not establish treatment-specific or causal effects. Larger randomized sham-controlled studies are needed to determine efficacy and clarify underlying neurophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.